- Cell & Gene Therapy CDMOs Address Manufacturing Complexity and Capacity Gaps — CGT market projected to reach $143.6 billion by 2034 (31% CAGR), driving demand for specialized manufacturing and supply-chain solutions.
- Sponsors engage CDMOs earlier in development to access GMP infrastructure, regulatory expertise, and modality-specific capabilities—particularly for RNA/LNP therapies and autologous cell therapies.
- CDMOs offer risk reduction, supply-chain resilience, and process knowledge preservation during ownership transitions and scale-up to commercial production.
Operational Impact: Sponsors are shifting outsourcing decisions toward CDMOs with multi-site global networks and specialized expertise in complex modalities (AAV, autologous cell, in-vivo CAR-T); AGC Biologics and Andelyn Biosciences highlight the competitive advantage of modality-specific technical depth and supply-chain continuity.
- Single-Site Operations and Integrated Teams Reduce CDMO Partnership Risk — Multi-site CDMOs with fragmented handoffs and siloed teams amplify risk through communication gaps and knowledge loss across development phases.
- Purpose-built single-site facilities like Upperton's Trent Gateway maintain continuous program teams and technical memory from research through GMP manufacturing.
- Integrated project management embedded within scientific execution enables proactive risk identification rather than reactive problem-solving.
Operational Impact: Biotech sponsors evaluating CDMO partners should prioritize single-site operations with co-located development and manufacturing teams, as Upperton's model demonstrates how facility design and team continuity directly reduce timeline delays and deviation risk.